NEW YORK – Cancer diagnostic firm Tracer Biotechnologies said recently that it has signed a multiyear agreement with AstraZeneca to use Tracer's technology for clinical trials.
Tracer has developed a proprietary platform for tumor-informed circulating-tumor DNA detection using digital PCR. The firm's assay is available for use with blood samples and urine samples, the company said in a statement.
"We are entering a new era of oncology where patients will no longer have to wait for costly and imprecise radiographic scans to assess treatment and disease progression," Tracer Biotechnologies CEO Mark Kaganovich said. "We are proud to work with AstraZeneca to leverage frequent, precise, and cost-effective ctDNA measurement for minimal residual disease detection and treatment response monitoring."
Financial and other terms of the deal were not disclosed.